VBL Therapeutics to Participate at Upcoming Virtual Investor Conferences
March 08 2021 - 7:00AM
VBL Therapeutics (Nasdaq: VBLT) today announced the Company will
participate in the following upcoming virtual investor conferences:
H.C Wainwright Global Life Sciences
ConferenceTuesday, March 9, 2021Presentation available
on-demand beginning at 7:00 a.m. ET
33rd Annual Roth ConferenceDate: Monday, March
15, 2021Panel discussion time: 10:00 a.m. ETTitle: Cancer –
Heterogeneous Approaches to a Heterogeneous Etiology
31st Annual Oppenheimer Healthcare Conference
Date: Tuesday, March 16, 2021Fireside chat time: 8:00 a.m. ET
Webcasts will be available via the Events and Presentations
section of the Company’s Investor Relations page.
About VBLVascular Biogenics Ltd., operating
as VBL Therapeutics, is a clinical stage biopharmaceutical
company focused on the discovery, development and commercialization
of first-in-class treatments for areas of unmet need in cancer and
immune/inflammatory indications. VBL has developed three platform
technologies: a gene-therapy based technology for targeting newly
formed blood vessels with focus on cancer, an antibody-based
technology targeting MOSPD2 for anti-inflammatory and
immuno-oncology applications, and the Lecinoxoids, a family of
small-molecules for immune-related indications. VBL’s lead oncology
product candidate, ofranergene obadenovec (VB-111), is an
investigational, first-in-class, targeted anti-cancer gene-therapy
agent that is being developed to treat a wide range of solid
tumors. VB-111 is currently being studied in a VBL-sponsored Phase
3 potential registration trial for platinum-resistant ovarian
cancer.
Forward Looking Statements This press release
contains forward-looking statements. All statements other than
statements of historical fact are forward-looking statements, which
are often indicated by terms such as “anticipate,” “believe,”
“could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,”
“may,” “plan,” “potential,” “predict,” “project,” “should,” “will,”
“would” and similar expressions. These forward-looking statements
may include, but are not limited to, statements regarding our
programs, including VB-111, including their clinical development,
therapeutic potential and clinical results. These forward-looking
statements are not promises or guarantees and involve substantial
risks and uncertainties. Among the factors that could cause actual
results to differ materially from those described or projected
herein include uncertainties associated generally with research and
development, clinical trials and related regulatory reviews and
approvals, the risk that historical clinical trial results may not
be predictive of future trial results, that our financial resources
do not last for as long as anticipated, and that we may not realize
the expected benefits of our intellectual property protection. In
particular, the DSMC recommendation that the OVAL trial proceed is
not assurance that the trial will meet its primary endpoint of
overall survival once completed, or that we will obtain positive
results to support further development of this candidate. A
further list and description of these risks, uncertainties and
other risks can be found in our regulatory filings with the U.S.
Securities and Exchange Commission, including in our annual report
on Form 20-F for the year ended December 31, 2019, and subsequent
filings with the SEC. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. VBL
Therapeutics undertakes no obligation to update or revise the
information contained in this press release, whether as a result of
new information, future events or circumstances or
otherwise.
CONTACT:Burns McClellan for VBL
TherapeuticsLee Roth (investors) / Ryo Imai
(media)lroth@burnsmc.com / rimai@burnsmc.com+1-212-213-0006
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Apr 2023 to Apr 2024